Targeted drug before surgery shows promise for RET-Altered thyroid cancer
NCT ID NCT04759911
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether giving selpercatinib before standard surgery can shrink tumors in people with RET-altered thyroid cancer. About 30 participants with advanced or recurrent disease will receive the drug and then undergo surgery. The goal is to see if the drug improves tumor response and surgical outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Selpercatinib (a targeted drug that blocks cancer growth)
- What this could lead to
- If successful, this approach could shrink thyroid tumors before surgery, making them easier to remove and potentially improving long-term disease control.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply to all patients. Selpercatinib may cause side effects, and not all tumors may respond.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT THYROID GLAND NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Michigan Health Systems
Ann Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Massive database study probes link between popular diabetes drugs and rare thyroid cancer
- New PET tracer could spot cancers that standard scans overlook
- New imaging agent could improve detection of rare cancers
- Could a smaller surgery spare medullary thyroid cancer patients from lifelong pills?
- New hope for advanced thyroid cancer: drug shows tumor-shrinking promise
- New radioactive therapy targets hard-to-treat thyroid cancer